PhaseBio Pharmaceuticals Issuance/Purchase of Shares

Issuance/Purchase of Shares of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Issuance/Purchase of Shares growth rates and interactive chart.


Highlights and Quick Summary

  • Issuance/Purchase of Shares for the quarter ending June 29, 2021 was $238 Thousand (a -99.61% decrease compared to previous quarter)
  • Year-over-year quarterly Issuance/Purchase of Shares decreased by -90.46%
  • Annual Issuance/Purchase of Shares for 2020 was $3.22 Million (a -93.07% decrease from previous year)
  • Annual Issuance/Purchase of Shares for 2019 was $46.5 Million (a -23.49% decrease from previous year)
  • Annual Issuance/Purchase of Shares for 2018 was $60.8 Million (a 2026633.33% increase from previous year)
  • Twelve month Issuance/Purchase of Shares ending June 29, 2021 was $63.5 Million (a -0.37% decrease compared to previous quarter)
  • Twelve month trailing Issuance/Purchase of Shares increased by 2011.34% year-over-year
Trailing Issuance/Purchase of Shares for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$63.5 Million $63.7 Million $3.22 Million $3.01 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Issuance/Purchase of Shares of PhaseBio Pharmaceuticals

Most recent Issuance/Purchase of Sharesof PHAS including historical data for past 10 years.

Interactive Chart of Issuance/Purchase of Shares of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Issuance/Purchase of Shares for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.24 $60.54
2020 $0.24 $2.49 $0.47 $0.02 $3.22
2019 $0.02 $0.06 $46.43 $46.52
2018 $43.02 $17.78 $60.8
2017 $0.0 $0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.